Twist Bioscience Corp. shares approached a 52-week high of $143.10 on Tuesday, trading at $143.35, just 0.96% below the peak. The genetic synthesis company’s stock has rallied 438% over the past 12 months and 349% year-to-date, reflecting strong investor interest in its AI-driven biotechnology applications.
The company’s market capitalization stands at $8.94 billion, with a beta of 2.16 indicating above-average volatility. In its fiscal third-quarter results for 2026, Twist Bioscience reported revenue of $118.4 million, exceeding Wall Street’s estimate of $114.54 million. However, adjusted losses deepened to $0.56 per share, compared with a forecasted loss of $0.48.
Twist Bioscience also highlighted its 14th consecutive quarter of sequential revenue growth, underscoring its operational momentum. The company entered a stock purchase agreement with Invenra Inc., allowing for the resale of shares under a Registration Rights Agreement. Additionally, Twist Bioscience served as an independent evaluator for Anthropic’s AI protein design initiative, producing and testing AI-generated proteins as part of the collaboration.
Short seller Scorpion Capital questioned the significance of the Anthropic partnership, suggesting it may not represent a major AI drug-discovery collaboration. Meanwhile, InvestingPro analysis flagged Twist Bioscience as potentially overvalued relative to its Fair Value estimate, placing it on a list of the most overvalued stocks.
